Sirnaomics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Sirnaomics Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Sirnaomics presents a practical BD-screening case because its returned pipeline contains 47 records and the deal search returned 3 transaction records. The lead returned asset is Pixofisiran/Lixadesiran, associated with COX-2 x TGF-β1 and Cutaneous Squamous Cell Carcinoma, Keloid, at Phase 2. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Pixofisiran/Lixadesiran | Sirnaomics, Inc. | Phase 2 | Pipeline record: COX-2 x TGF-β1; Cutaneous Squamous Cell Carcinoma, Keloid. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines | Phase 2 asset with COX-2 x TGF-β1 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | STP-122G | Sirnaomics Ltd. | Phase 1 | Pipeline record: F11; Blood Coagulation Disorders, Metabolic Diseases. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702 | Phase 1 asset with F11 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | STP-707 | Sirnaomics, Inc. | Phase 1 | Pipeline record: COX-2 x TGF-β1; Liver Cirrhosis, Advanced Malignant Solid Neoplasm. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. acquires Guangzhou Natai Biomedical Technology Co., Ltd. | Phase 1 asset with COX-2 x TGF-β1 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | RV-1770 | Sirnaomics Ltd. | IND Approval | Pipeline record: target not returned; Respiratory Syncytial Virus Infections. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines | IND Approval asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | STP-125G | Sirnaomics, Inc. | IND Application | Pipeline record: APOC3; Hypertriglyceridemia, Cardiovascular Diseases. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702 | IND Application asset with APOC3 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2025-09-07 | Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines | Active | total_amount: 17.71; disclosed: false |
| 2021-04-29 | Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702 | Active | total_amount: 6.4; disclosed: false |
| Date not returned | Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. acquires Guangzhou Natai Biomedical Technology Co., Ltd. | Completed | total_amount: 0.34; disclosed: false |
The most relevant returned precedent is: Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines (2025-09-07). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- Sirnaomics Ltd. - 财务资料: Sirnaomics Ltd. - 财务资料 我们的成本结构 于2019年、2020年以及截至2021年5月31日止五个月，我们的行政开支分别为4.7百万美 元、5.2百万美元及3.9百万美元。我们的行政开支主要包括：(i)董事薪酬及员工成本；及(ii) 专业及咨询费。请参阅「— 经营业绩主要组成部分的描述 — 行政开支」。 我们预期至少于未来数年会产生大量开支及净亏损，原因在于我们进一步推进临床前 及临床研发工作，继续进行候选药物的临床开发并寻求监管批准，开始管线产品的商业化， 本文件为草拟本，其所载资料并不完整及可作更改，阅读本文件有关资料时，必须一并细 阅本文件首页「警告」一节。 以及招揽运营业务所需的新人员。我们预期，因候选药物的开发状态、监管批准时间表以 及候选药物获批后商业化的影响，我们的财务表现将不定期出现波动。上市后，我们预期 将产生与作为上市公司运营相关的成本。 为我们的营运提供资金 于往绩记录期间，我们主要通过私募股权融资满足营运资金需求。日后，倘成功商业 化，我们预期以销售药品产生的收入以及任何合作及许可安排的特许权使用费为我们的运 营拨付部分资金。随著业务的持续拓展，我们可能需要通过公开或私人股权发售、债务融 资或其他来源进一步融资。倘若我们为运营融资的能力出现任何波动，将会对我们的现金 流计划及经营业绩造成影响。 重大会计政策及关键会计判断及估计不确定性的主要来源 Sirnaomics Ltd. - 财务资料 关键财务比率 下表载列截至所示日期我们的关键财务比率： 流动比率 (1) 附注： (1) 流动比率指截至同日的流动资产除以流动负债。 请参阅「— 综合财务状况表主要项目的讨论」。 本文件为草拟本，其所载资料并不完整及可作更改，阅读本文件有关资料时，必须一并细 阅本文件首页「警告」一节。 流动资金及资本资源 营运资金 于往绩记录期间，我们的流动
- Sirnaomics Ltd. - 概要: Sirnaomics Ltd. - 概要 经营业绩摘选数据 下表载列截至所示日期自我们综合财务状况表节选的资料： 流动资产总值 非流动资产总值 资产总值 流动负债总额 非流动负债总额 负债总额 负债净额 截至12月31日止年度 截至5月31日止五个月 截至12月31日 本文件为草拟本，其所载资料并不完整及可作更改，阅读本文件有关资料时，必须一并细 阅本文件首页「警告」一节。 请参阅「财务资料 — 综合财务状况表主要项目的讨论」。 综合现金流量表摘选数据 下表载列于所示期间我们的现金流量： 经营活动所用现金净额 投资活动所得╱（所用） 现金净额 融资活动所得现金净额 增加净额 汇率变动影响 请参阅「财务资料 — 流动资金及资本资源 — 现金流量」。 我们的现金消耗率指(i)经营活动所用的现金净额，包括研发费用；(ii)厂房及设备的购 买金额及就此支付的按金；(iii)偿还租赁负债；(iv)购买无形资产的费用；及(v)支付利息的月 均累计金额。假设日后的平均现金消耗率为2020年水平的5.2倍，我们估计截至2021年5月31 日的现金及现金等价物，连同我们于2021年7月完成的E系列融资所得款项106.7百万美元， 将能够维持我们约20.9个月或（倘我们亦考虑[编纂]的估计所得款项净额（基于指示性[编纂] 中位数））约52.2个月内的财务能力。我们的董事及管理团队将继续监控我们的营运资金、 现金流量及业务发展动态。 截至12月31日止年度 截至5月31日止五个月 本文件为草拟本，其所载资料并不完整及可作更改，阅读本文件有关资料时，必须一并细 阅本文件首页「警告」一节。
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Sirnaomics is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Sirnaomics merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Pixofisiran/Lixadesiran, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
